November 1, 2016
Allergan closes down Tobira purchace
Allergan has completed the acquisition of Tobira Therapeutics
Pharmaceuticals, Biotechnology and Life Sciences
Tag: David Nicholson
October 31, 2016
Allergan’s chronic dry eye drops will make patients shed more tears
Allergan has received approval from the FDA for Restasis, treatment to help patients with a type of Chronic Dry Eye …
October 25, 2016
Allergan completes acquisition of Vitae
Allergan successfully completed its tender offer to purchase …
March 17, 2016
Allergan: FDA approves Vraylartm
Allergan’s Vraylartm (cariprazine), a once-daily oral atypical antipsychotic, is now available by prescription in pharmacies throughout the U.S. As Allergan…
November 16, 2015
Allergan’s Bimatoprost lowers intraocular pressure in glaucoma patients (Phase I/II trial)
A single dose of Bimatoprost Sustained-Release (SR) lowered intraocular pressure (IOP) in 92 percent (n= 69) of glaucoma patients at 4 months and 71 percent (n=53) at 6 months while demonstrating a favorable efficacy and safety profile.
November 11, 2015
Allergan submits Prior Approval Supplement for RESTASIS
Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.
October 9, 2015
FDA Accepts Allergan’s Supplemental New Drug Application (sNDA) for DALVANCE
Allergan plc has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Allergan’s supplemental New Drug Application (sNDA), for MRSA.
September 23, 2015
Phase 3 study of ABP 215 meets its endpoints
Amgen and Allergan plc. announced on Wednesday that a Phase 3 study of biosimilar candidate ABP 215 met its primary…
September 17, 2015
FDA approves Vraylar for treatment of bipolar I disorder and schizophrenia
Allergan plc and Gedeon Richter Plc. have announced that the U.S. Food and Drug Administration (FDA) has approved Vraylartm (cariprazine) capsules,…